Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Extended Drug Therapy for Hepatitis Is Challenged
Patients who do not initially respond to standard drug therapy for treatment of hepatitis C are unlikely to respond to long-term maintenance therapy as well, according to a new study. Yet many patients who do not at first respond to drugs are placed on

Gilead Sciences, Inc. (GILD) Release: Data Demonstrating Significant Efficacy of Viread(R) in Treating Chronic Hepatitis B Published in New England Journal of Medicine
FOSTER CITY, Calif.--(BUSINESS WIRE)-- (Nasdaq: GILD) today announced the publication of detailed 48-week data from two Phase III pivotal clinical trials evaluating the safety and efficacy of its once-daily Viread (tenofovir disoproxil fumarate) for the

Interferon as long-term treatment for hepatitis C not effective
Results of the 3-year study, called the HALT-C (Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis) Trial, appear in today's issue of . The researchers found no difference in the rate of progression of liver disease among patients who received

UPDATES AND COMMENTARY RSS Feed

Hep C Study Reveals Taribavirin a Good Alternative to Ribavirin
At the end of a 48-week, Phase IIb study, taribavirin shows similar effectiveness as ribavirin in reducing Hepatitis C viral load. However, participants taking taribavirin had a significantly lower rate of anemia....

Schering-Plough Developing Potent Protease Inhibitor for Hepatitis C
An ongoing Phase IIa study on Schering-Plough's next generation Hepatitis C protease inhibitor is encouraging. According to the company, SCH 900518 is 10 times more potent than other medications in this class and is active against highly resistant Hepatitis C...

New Drug Finds Viral Hiding Spots
A new, experimental drug helps the immune system locate a virus by flagging cells that have turned inside out. Hepatitis C is among the viruses that could benefit from Bavituximab's unique strategy of exposing a virus in hiding....

References & Appendix

Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Sclerotherapy for the Prevention of Variceal Bleeding in Cirrhosis: A Randomized Multicenter Trial

1. Pagliaro L, D'Amico G, Pasta L, Politi F, Vizzini G, Traina M, Madonia S, et al. Portal hypertension in cirrhosis: natural history. In: Bosch J, Groszmann RJ, eds. Portal Hypertension, Pathophysiology and Treatment. Oxford, UK: Blackwell Scientific Publications, 1994:72-92.

2. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. HEPATOLOGY 1995; 22: 332-354[ [ Link previously at www.ncbi.nlm.nih.gov ]].

3. In: de Franchis R, ed. Portal Hypertension II. Proceedings of the IInd Baveno international consensus workshop on definitions, methodology and therapeutic strategies. Oxford, UK: Blackwell Science, 1996.

4. Richter GM, Nldge G, Palmaz JC, et al. Transjugular intrahepatic portacaval stent shunt: preliminary clinical results. Radiology 1990; 174: 1027-1030[ Medline].

5. Rössle M, Haag K, Ochs A, et al. The transjugular intrahepatic portosystemic stent shunt procedure for variceal bleeding. N Engl J Med 1994; 330: 165-171[ [ Link previously at www.ncbi.nlm.nih.gov ]].

6. LaBerge J, Somberg KA, Lake JR, Gordon RL, Kerlan RK, Ascher NL, Roberts JP, et al. Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients. Gastroenterology 1995; 108: 1143-1151[ Abstract].

7. McCormick PA, Dick R, Panagou EB, et al. Emergency transjugular intrahepatic portosystemic stent shunting as a salvage treatment for uncontrolled variceal bleeding. Br J Surg 1994; 81: 1324-1327[ [ Link previously at www.ncbi.nlm.nih.gov ]].

8. Ochs A, Rssle M, Haag K, Hauenstein KD, Deibert P, Siegerstetter V, Huanker M, et al. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332: 1192-1197[ [ Link previously at www.ncbi.nlm.nih.gov ]].

9. Ochs A, Sellinger M, Haag K, Noldge G, Herbst EW, Walter E, Gerok W, et al. Transjugular intrahepatic portosystemic stent-shunt (TIPS) in the treatment of Budd-Chiari syndrome. J Hepatol 1993; 18: 217-225[ [ Link previously at www.ncbi.nlm.nih.gov ]].

10. Ring E, Lake JR, Roberts JP, Gordon RL, LaBerge JM, Read AE, Sterneck MR. Using transjugular intrahepatic portosystemic shunt to control variceal bleeding before liver transplantation. Ann Intern Med 1992; 116: 304-309[ [ Link previously at www.ncbi.nlm.nih.gov ]].

11. Cabrera J, Maynar M, Granados R, Gorriz E, Reyes R, Pulido-Duque JM, Rodriguez Sanroman JL, et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology 1996; 110: 832-839[ Abstract].

12. Lee WM. Intrahepatic portacaval shunts: a new era? Gastroenterology 1992; 103: 1357-1358[ [ Link previously at www.ncbi.nlm.nih.gov ]].

13. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1991; 80: 800-809[ Abstract].

14. Parsons-Smith BG, Summerskill WHJ, Dawson AM, Sherlock S. The electroencephalography in liver disease. Lancet 1952; 2: 867-871.

15. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol vs. placebo in the prevention of the first variceal hemorrhage. Gastroenterology 1990; 99: 1401-1407[ Abstract].

16. Feu F, Garcia Pagàn JC, Bosch J, Luca A, Terès J, Escorsell A, Rodès J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal hemorrhage in patients with cirrhosis. Lancet 1995; 346: 1056-1059[ [ Link previously at www.ncbi.nlm.nih.gov ]].

17. Sanyal AJ, Freedman AM, Shiffman ML, Purdum III PP, Luketic VA, Chatham AK. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. HEPATOLOGY 1994; 20: 46-55[ Medline].

18. Riggio O, Merli M, Pedretti G, Servi R, Meddi P, Lionetti R, Rossi P, Bezzi M, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: incidence and risk factors. Dig Dis Sci 1996; 41: 578-584[ [ Link previously at www.ncbi.nlm.nih.gov ]].

19. Lind CD, Malisch TW, Chong WK, Richards WO, Pinson CW, Meranze SG, Mazer M. Incidence of shunt occlusion or stenosis following transjugular intrahepatic postosystemic shunt placement. Gastroenterology 1994; 106: 1277-1283[ Abstract].

Return To Article

APPENDIX

The following investigators are also members of the Gruppo Italiano Studio TIPS (G.I.S.T.) and took part in the study:

Bruno Andreoni, M.D., Emergency Surgery, IRCCS, Ospedale Maggiore, University of Milan; Genoveffa Balducci, M.D., Institute of I General Surgery, University La Sapienza, Rome; Marco Bianchi, M.D., Institute of Internal Medicine, University of Milan; Antonio Bolognese, M.D., Institute of I General Surgery, University La Sapienza, Rome; Maurizio Cardi, M.D., Institute of I General Surgery, University La Sapienza, Rome; Massimo Cazzaniga, M.D., Institute of Internal Medicine, University of Milan; Anna Maria Degli Antoni, M.D., Institute of Radiological Sciences, University of Parma; Adriano De Santis, M.D., Institute of II Gastroeneterology, La Sapienza University, Rome; Emilio Di Giulio, M.D., Institute of I General Surgery, University La Sapienza, Rome; Raffaella Lionetti, M.D., Institutes of II Gastroeneterology, La Sapienza University, Rome; Antonio Nicolini, M.D., University of Milan Radiology Department, IRCCS Ospedale Maggiore, Milan; Barbara Ostan, M.D., Institute of Internal Medicine, University of Milan; Vittorio Rinaldi, M.D., Institute of II Gastroenterology, La Sapienza University, Rome; Silvia Saccheri, M.D., University of Milan Radiology Department, IRCCS Ospedale Maggiore, Milan; Roberta Servi, M.D., Institute of II Gastroenterology, La Sapienza University, Rome; Angela Stasio, M.D., Institute of I General Surgery, University La Sapienza, Rome; Vincenzo Ziparo, M.D., Institute of I General Surgery, La Sapienza University, Rome.

1270-9139/98/2701-0009$3.00/0

Copyright © 1998 by the American Association for the Study of Liver Diseases.

table Of Contents

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 05 Dec 2008